NCT02461771View on ClinicalTrials.gov

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

March 8, 2016

Study Completion Date

March 8, 2016

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

Pegcetacoplan

On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

Trial Locations (4)

2150

Australia, New South Wells, Parramatta

33136

United States, Florida, Miami

90211

United States, California, Beverly Hills

03801

United States, New Hampshire, Portsmouth

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY